KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) EPS (Weighted Average and Diluted) (2016 - 2025)

Fulgent Genetics' EPS (Weighted Average and Diluted) history spans 10 years, with the latest figure at -$0.77 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 305.26% year-over-year to -$0.77; the TTM value through Dec 2025 reached -$1.97, down 39.72%, while the annual FY2025 figure was -$1.97, 39.72% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.77 at Fulgent Genetics, down from -$0.21 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $6.52 in Q1 2021 and bottomed at -$4.3 in Q4 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.33 (2024), against an average of $0.6.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 7344.44% in 2021 before it plummeted 816.67% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $3.34 in 2021, then crashed by 123.95% to -$0.8 in 2022, then crashed by 437.5% to -$4.3 in 2023, then soared by 95.58% to -$0.19 in 2024, then tumbled by 305.26% to -$0.77 in 2025.
  • Per Business Quant, the three most recent readings for FLGT's EPS (Weighted Average and Diluted) are -$0.77 (Q4 2025), -$0.21 (Q3 2025), and -$0.62 (Q2 2025).